News
Over 3 years, SGLT2 inhibitors were safely associated with a nearly one third reduction in the risk for serious liver events.
Results that may be inaccessible to you are currently showing.
Hide inaccessible resultsResults that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback